From science to optimized care

Bespoke SaMD development, ready to scale with your needs. Enter with an idea, an unmet clinical need or an algorithm. Leave with a product ready for market.

Co-develop with us

Guide therapy with real-world data

  • Digital biomarkers

    Clinically validated digital biomarkers support diagnosis with fast, detailed, and objective symptom quantification.

  • Clinical monitoring

    Automatic tracking of multiple digital biomarkers over time provides insight into patient treatment response.

  • Treatment optimization

    Clinical decision support algorithms enable evidence-based treatment guidance.

Harness the power of sensors

Transform raw signals into healthcare insights. We help you turn everyday sensors into precise, clinical-grade tools. Extract meaningful data from motion, eye-tracking, and other physiological signals—without relying on vast datasets. And without the risks of black box AI models that can introduce bias.

 

ANLIVA® Hand Movement delivers consistent results using regular smartphone motion sensors.

Create, launch and scale at speed

  • Scalable

    Adapt to changing traffic and usage needs. Scale from pilot to global launch on the same digital infrastructure.

  • Modular

    Easily add new SaMD modules. Our isolated microservice architecture streamlines updates and expansions.

  • Rapid

    Go from algorithm prototype to final microservice with our fast track. No code changes or porting needed.

Take the smart route to regulatory approval

Combine agile development with clinical stringency. Track every iteration in line with regulatory demands – a digital quality system is deeply integrated into our process. And isolated microservices limit the need for documentation of product additions and changes.

  • There is a huge need for incorporating computerized selection and adjustment of DBS leads given the infinite possibilities that the neurologist has to deal with in reality of clinical practice. The current paradigm of adjusting DBS parameters is often based on a lengthy and manual trial-and-error procedure that depends on the subjective expertise of the clinician. Now that we started working on and planning for the clinical trial using ANLIVA DBS, that possibility became closer to actual application than ever.

    Anas Hannoun MD Clinical Assistant Professor of Neurology, Movement Disorders at Geisel School of Medicine at Dartmouth

Stay up-to-date

Sign up to receive updates on our latest developments.

    For information on how we process your data and protect your privacy, read our Privacy Policy.